View Financial HealthCentral Pharmaceuticals 配当と自社株買い配当金 基準チェック /06Central Pharmaceuticals現在配当金を支払っていません。主要情報0%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesReported Earnings • Jun 10Third quarter 2026 earnings releasedThird quarter 2026 results: Net loss: ৳10.4m (loss narrowed 8.4% from 3Q 2025).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 22Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 25Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026お知らせ • Nov 10Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025お知らせ • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttam sultan mahmud road, gulshan-02, dhaka-1212., Bangladeshお知らせ • Oct 22Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025お知らせ • Apr 21Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 23Central Pharmaceuticals Ltd. to Report Q2, 2025 Results on Jan 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025お知らせ • Nov 09Central Pharmaceuticals Ltd. to Report Q1, 2025 Results on Nov 14, 2024Central Pharmaceuticals Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024お知らせ • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttom sultan mahmud road, gulshan 02, dhaka-1212, Bangladeshお知らせ • Oct 23Central Pharmaceuticals Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Central Pharmaceuticals Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024New Risk • Oct 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.17b (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m (৳112m revenue, or US$931k). Market cap is less than US$10m (৳1.17b market cap, or US$9.78m).Reported Earnings • May 22Third quarter 2024 earnings releasedThird quarter 2024 results: ৳0.16 loss per share. Net loss: ৳19.6m (flat on 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.お知らせ • Apr 28Central Pharmaceuticals Ltd. to Report Q3, 2024 Results on Apr 30, 2024Central Pharmaceuticals Ltd. announced that they will report Q3, 2024 results on Apr 30, 2024Reported Earnings • Mar 12Second quarter 2024 earnings released: ৳0.09 loss per share (vs ৳0.08 loss in 2Q 2023)Second quarter 2024 results: ৳0.09 loss per share (further deteriorated from ৳0.08 loss in 2Q 2023). Net loss: ৳11.3m (loss widened 25% from 2Q 2023).お知らせ • Jan 26Central Pharmaceuticals Ltd. to Report Q2, 2024 Results on Jan 31, 2024Central Pharmaceuticals Ltd. announced that they will report Q2, 2024 results on Jan 31, 2024Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 07Central Pharmaceuticals Ltd. to Report Q1, 2024 Results on Nov 09, 2023Central Pharmaceuticals Ltd. announced that they will report Q1, 2024 results on Nov 09, 2023お知らせ • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time. Agenda: To consider No dividend for the year ended June 30, 2023.お知らせ • Oct 24Central Pharmaceuticals Ltd. to Report Fiscal Year 2023 Results on Oct 29, 2023Central Pharmaceuticals Ltd. announced that they will report fiscal year 2023 results on Oct 29, 2023New Risk • Jul 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$233k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (৳1.58b market cap, or US$14.6m).New Risk • Jul 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$232k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (৳1.41b market cap, or US$13.0m).Reported Earnings • Jan 15Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ৳0.072 loss per share (up from ৳9.24 loss in FY 2020). Revenue: ৳148.2m (up 5.8% from FY 2020). Net loss: ৳8.60m (loss narrowed 99% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Jan 04New 90-day high: ৳13.60The company is up 11% from its price of ৳12.20 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period.Reported Earnings • Dec 30Full year 2020 earnings released: ৳9.24 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: ৳140.1m (down 54% from FY 2019). Net loss: ৳1.11b (down ৳1.16b from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 121% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 19New 90-day high: ৳13.30The company is up 1.0% from its price of ৳13.20 on 20 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.お知らせ • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020, at 11:30 Bangladesh Standard Time.決済の安定と成長配当データの取得安定した配当: CENTRALPHLの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CENTRALPHLの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Central Pharmaceuticals 配当利回り対市場CENTRALPHL 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CENTRALPHL)0%市場下位25% (BD)0.8%市場トップ25% (BD)3.5%業界平均 (Pharmaceuticals)3.7%アナリスト予想 (CENTRALPHL) (最長3年)n/a注目すべき配当: CENTRALPHLは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CENTRALPHLは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CENTRALPHL BD市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: CENTRALPHLが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YBD 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/20 09:14終値2026/06/18 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Central Pharmaceuticals Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Jun 10Third quarter 2026 earnings releasedThird quarter 2026 results: Net loss: ৳10.4m (loss narrowed 8.4% from 3Q 2025).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 22Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 25Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026
お知らせ • Nov 10Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025
お知らせ • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttam sultan mahmud road, gulshan-02, dhaka-1212., Bangladesh
お知らせ • Oct 22Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
お知らせ • Apr 21Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 23Central Pharmaceuticals Ltd. to Report Q2, 2025 Results on Jan 29, 2025Central Pharmaceuticals Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025
お知らせ • Nov 09Central Pharmaceuticals Ltd. to Report Q1, 2025 Results on Nov 14, 2024Central Pharmaceuticals Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024
お知らせ • Nov 05Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttom sultan mahmud road, gulshan 02, dhaka-1212, Bangladesh
お知らせ • Oct 23Central Pharmaceuticals Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024Central Pharmaceuticals Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024
New Risk • Oct 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.17b (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m (৳112m revenue, or US$931k). Market cap is less than US$10m (৳1.17b market cap, or US$9.78m).
Reported Earnings • May 22Third quarter 2024 earnings releasedThird quarter 2024 results: ৳0.16 loss per share. Net loss: ৳19.6m (flat on 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
お知らせ • Apr 28Central Pharmaceuticals Ltd. to Report Q3, 2024 Results on Apr 30, 2024Central Pharmaceuticals Ltd. announced that they will report Q3, 2024 results on Apr 30, 2024
Reported Earnings • Mar 12Second quarter 2024 earnings released: ৳0.09 loss per share (vs ৳0.08 loss in 2Q 2023)Second quarter 2024 results: ৳0.09 loss per share (further deteriorated from ৳0.08 loss in 2Q 2023). Net loss: ৳11.3m (loss widened 25% from 2Q 2023).
お知らせ • Jan 26Central Pharmaceuticals Ltd. to Report Q2, 2024 Results on Jan 31, 2024Central Pharmaceuticals Ltd. announced that they will report Q2, 2024 results on Jan 31, 2024
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 07Central Pharmaceuticals Ltd. to Report Q1, 2024 Results on Nov 09, 2023Central Pharmaceuticals Ltd. announced that they will report Q1, 2024 results on Nov 09, 2023
お知らせ • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time. Agenda: To consider No dividend for the year ended June 30, 2023.
お知らせ • Oct 24Central Pharmaceuticals Ltd. to Report Fiscal Year 2023 Results on Oct 29, 2023Central Pharmaceuticals Ltd. announced that they will report fiscal year 2023 results on Oct 29, 2023
New Risk • Jul 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$233k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (৳1.58b market cap, or US$14.6m).
New Risk • Jul 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$232k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (৳1.41b market cap, or US$13.0m).
Reported Earnings • Jan 15Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ৳0.072 loss per share (up from ৳9.24 loss in FY 2020). Revenue: ৳148.2m (up 5.8% from FY 2020). Net loss: ৳8.60m (loss narrowed 99% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Jan 04New 90-day high: ৳13.60The company is up 11% from its price of ৳12.20 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period.
Reported Earnings • Dec 30Full year 2020 earnings released: ৳9.24 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: ৳140.1m (down 54% from FY 2019). Net loss: ৳1.11b (down ৳1.16b from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 121% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 19New 90-day high: ৳13.30The company is up 1.0% from its price of ৳13.20 on 20 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
お知らせ • Nov 06Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020, at 11:30 Bangladesh Standard Time.